6.
Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin D
. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013; 14(11):1077-1085.
DOI: 10.1016/S1470-2045(13)70154-2.
View
7.
Braendengen M, Tveit K, Berglund A, Birkemeyer E, Frykholm G, Pahlman L
. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008; 26(22):3687-94.
DOI: 10.1200/JCO.2007.15.3858.
View
8.
Puccini A, Lenz H, Marshall J, Arguello D, Raghavan D, Korn W
. Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Oncologist. 2018; 24(3):319-326.
PMC: 6519749.
DOI: 10.1634/theoncologist.2018-0117.
View
9.
Clegg A, Young J, Iliffe S, Rikkert M, Rockwood K
. Frailty in elderly people. Lancet. 2013; 381(9868):752-62.
PMC: 4098658.
DOI: 10.1016/S0140-6736(12)62167-9.
View
10.
Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H
. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2023; 329(15):1271-1282.
PMC: 10114040.
DOI: 10.1001/jama.2023.4428.
View
11.
Folstein M, Folstein S, McHugh P
. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98.
DOI: 10.1016/0022-3956(75)90026-6.
View
12.
Tomasello G, Ghidini M, Galassi B, Grossi F, Luciani A, Petrelli F
. Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis. Sci Rep. 2022; 12(1):1055.
PMC: 8776729.
DOI: 10.1038/s41598-022-05065-6.
View
13.
Paun B, Cassie S, MacLean A, Dixon E, Buie W
. Postoperative complications following surgery for rectal cancer. Ann Surg. 2010; 251(5):807-18.
DOI: 10.1097/SLA.0b013e3181dae4ed.
View
14.
Sargent D, Goldberg R, JACOBSON S, Macdonald J, Labianca R, Haller D
. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345(15):1091-7.
DOI: 10.1056/NEJMoa010957.
View
15.
Van Cutsem E, Mayer R, Laurent S, Winkler R, Gravalos C, Benavides M
. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2017; 90:63-72.
PMC: 7493695.
DOI: 10.1016/j.ejca.2017.10.009.
View
16.
Lieu C, Kennedy E, Bergsland E, Berlin J, George T, Gill S
. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019; 37(16):1436-1447.
DOI: 10.1200/JCO.19.00281.
View
17.
Diaz Jr L, Shiu K, Kim T, Jensen B, Jensen L, Punt C
. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022; 23(5):659-670.
PMC: 9533375.
DOI: 10.1016/S1470-2045(22)00197-8.
View
18.
Leighl N, Nirmalakumar S, Ezeife D, Gyawali B
. An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access. Am Soc Clin Oncol Educ Book. 2021; 41:1-12.
DOI: 10.1200/EDBK_100028.
View
19.
Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L
. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. J Clin Oncol. 2022; 40(25):2878-2888.
PMC: 9426812.
DOI: 10.1200/JCO.22.00839.
View
20.
Aparicio T, Gargot D, Teillet L, Maillard E, Genet D, Cretin J
. Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. Eur J Cancer. 2016; 74:98-108.
DOI: 10.1016/j.ejca.2016.09.029.
View